Beta Drugs Limited (NSE:BETA)

Beta Drugs Statistics

Total Valuation

Beta Drugs has a market cap or net worth of INR 16.93 billion. The enterprise value is 16.79 billion.

Market Cap	16.93B
Enterprise Value	16.79B

Important Dates

The next estimated earnings date is Wednesday, August 6, 2025.

Earnings Date	Aug 6, 2025
Ex-Dividend Date	n/a

Share Statistics

Beta Drugs has 10.09 million shares outstanding. The number of shares has increased by 0.00% in one year.

Current Share Class	10.09M
Shares Outstanding	10.09M
Shares Change (YoY)	+0.00%
Shares Change (QoQ)	+0.02%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	n/a

Valuation Ratios

The trailing PE ratio is 39.91.

PE Ratio	39.91
Forward PE	n/a
PS Ratio	4.67
PB Ratio	8.59
P/TBV Ratio	8.98
P/FCF Ratio	n/a
P/OCF Ratio	46.80
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 22.50, with an EV/FCF ratio of -2,447.15.

EV / Earnings	39.57
EV / Sales	4.63
EV / EBITDA	22.50
EV / EBIT	27.03
EV / FCF	-2,447.15

Financial Position

The company has a current ratio of 3.22, with a Debt / Equity ratio of 0.67.

Current Ratio	3.22
Quick Ratio	2.43
Debt / Equity	0.67
Debt / EBITDA	1.78
Debt / FCF	-193.48
Interest Coverage	8.88

Financial Efficiency

Return on equity (ROE) is 23.95% and return on invested capital (ROIC) is 15.47%.

Return on Equity (ROE)	23.95%
Return on Assets (ROA)	11.24%
Return on Invested Capital (ROIC)	15.47%
Return on Capital Employed (ROCE)	18.62%
Revenue Per Employee	9.77M
Profits Per Employee	1.14M
Employee Count	371
Asset Turnover	1.05
Inventory Turnover	3.87

Taxes

In the past 12 months, Beta Drugs has paid 145.50 million in taxes.

Income Tax	145.50M
Effective Tax Rate	25.54%

Stock Price Statistics

The stock price has increased by +45.11% in the last 52 weeks. The beta is -0.17, so Beta Drugs's price volatility has been lower than the market average.

Beta (5Y)	-0.17
52-Week Price Change	+45.11%
50-Day Moving Average	1,796.68
200-Day Moving Average	1,814.83
Relative Strength Index (RSI)	34.17
Average Volume (20 Days)	4,310

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Beta Drugs had revenue of INR 3.62 billion and earned 424.19 million in profits. Earnings per share was 42.02.

Revenue	3.62B
Gross Profit	1.50B
Operating Income	620.91M
Pretax Income	569.69M
Net Income	424.19M
EBITDA	746.05M
EBIT	620.91M
Earnings Per Share (EPS)	42.02

Balance Sheet

The company has 1.47 billion in cash and 1.33 billion in debt, giving a net cash position of 143.16 million or 14.18 per share.

Cash & Cash Equivalents	1.47B
Total Debt	1.33B
Net Cash	143.16M
Net Cash Per Share	14.18
Equity (Book Value)	1.97B
Book Value Per Share	195.22
Working Capital	2.28B

Cash Flow

In the last 12 months, operating cash flow was 361.73 million and capital expenditures -368.59 million, giving a free cash flow of -6.86 million.

Operating Cash Flow	361.73M
Capital Expenditures	-368.59M
Free Cash Flow	-6.86M
FCF Per Share	-0.68

Margins

Gross margin is 41.50%, with operating and profit margins of 17.14% and 11.71%.

Gross Margin	41.50%
Operating Margin	17.14%
Pretax Margin	15.72%
Profit Margin	11.71%
EBITDA Margin	20.59%
EBIT Margin	17.14%
FCF Margin	n/a

Dividends & Yields

Beta Drugs does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.00%
Shareholder Yield	n/a
Earnings Yield	2.51%
FCF Yield	-0.04%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on March 26, 2025. It was a forward split with a ratio of 1.05.

Last Split Date	Mar 26, 2025
Split Type	Forward
Split Ratio	1.05

Scores

Altman Z-Score	n/a
Piotroski F-Score	5